Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 21, 2024 (filed on Mar 22, 2024)Insider Name:Abel Robert LorneOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:30,000Price:--
-
Mar 21, 2024 (filed on Mar 22, 2024)Insider Name:Lorton Kenneth PatrickOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:30,000Price:--
-
Mar 06, 2024 (filed on Mar 07, 2024)Insider Name:Lorton Kenneth PatrickOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-5,574Price:--
-
Mar 06, 2024 (filed on Mar 07, 2024)Insider Name:Lorton Kenneth PatrickOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:5,574Price:$4.34
-
Mar 04, 2024 (filed on Mar 05, 2024)Insider Name:Porges Geoffrey CraigOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:90,000Price:--
-
Mar 04, 2024 (filed on Mar 05, 2024)Insider Name:Porges Geoffrey CraigOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-3,315Price:$26.35
-
Mar 04, 2024 (filed on Mar 05, 2024)Insider Name:Porges Geoffrey CraigOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:9,000Price:--
-
Mar 04, 2024 (filed on Mar 05, 2024)Insider Name:Farid RamyOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:87,271Price:--
-
Mar 04, 2024 (filed on Mar 05, 2024)Insider Name:Farid RamyOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:126,000Price:--
-
Mar 04, 2024 (filed on Mar 05, 2024)Insider Name:Herman JennyOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:14,625Price:--
Filings by filing date
-
Mar 21, 2024 (filed on Mar 22, 2024)Insider Name:Abel Robert LorneOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:30,000Price:--
-
Mar 21, 2024 (filed on Mar 22, 2024)Insider Name:Lorton Kenneth PatrickOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:30,000Price:--
-
Mar 06, 2024 (filed on Mar 07, 2024)Insider Name:Lorton Kenneth PatrickOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-5,574Price:--
-
Mar 06, 2024 (filed on Mar 07, 2024)Insider Name:Lorton Kenneth PatrickOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:5,574Price:$4.34
-
Mar 04, 2024 (filed on Mar 05, 2024)Insider Name:Porges Geoffrey CraigOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:90,000Price:--
-
Mar 04, 2024 (filed on Mar 05, 2024)Insider Name:Porges Geoffrey CraigOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-3,315Price:$26.35
-
Mar 04, 2024 (filed on Mar 05, 2024)Insider Name:Porges Geoffrey CraigOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:9,000Price:--
-
Mar 04, 2024 (filed on Mar 05, 2024)Insider Name:Farid RamyOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:87,271Price:--
-
Mar 04, 2024 (filed on Mar 05, 2024)Insider Name:Farid RamyOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:126,000Price:--
-
Mar 04, 2024 (filed on Mar 05, 2024)Insider Name:Herman JennyOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:14,625Price:--
News
Biz Brief
Sector: Technology | Industry: Software |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1540 BROADWAY, 24TH FLOOR NEW YORK NY 10036 |
Tel: | N/A |
Website: | https://www.schrodinger.com |
IR: | See website |
Key People | ||
Ramy Farid President, Chief Executive Officer, Director | Geoffrey Porges Chief Financial Officer, Executive Vice President | Karen Akinsanya President - R&D Therapeutics |
Kenneth Patrick Lorton Executive Vice President, Chief Technology Officer | Yvonne Tran Executive Vice President, Chief Legal Officer, Corporate Secretary | Robert Abel Executive Vice President, Chief Computational Scientist, Head of Modeling Research and Development | Margaret Dugan Chief Medical Officer |
Business Overview |
Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. The Company operates through two segments: Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor). Its software was used by researchers around the world at more than 1,760 academic institutions. |
Financial Overview |
For the fiscal year ended 31 December 2023, Schrodinger Inc revenues increased 20% to $216.7M. Net income totaled $40.7M vs. loss of $149.2M. Revenues reflect Software segment increase of 17% to $159.1M, Drug discovery segment increase of 27% to $57.5M, United States segment increase of 31% to $162M, APAC segment increase of 13% to $24.6M. Net Income reflects Gain (loss) on equity investments increase from $11.8M to $147.2M (income). |
Employees: | 867 as of Feb 5, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,275M as of Dec 31, 2023 |
Annual revenue (TTM): | $216.67M as of Dec 31, 2023 |
EBITDA (TTM): | -$171.90M as of Dec 31, 2023 |
Net annual income (TTM): | $40.72M as of Dec 31, 2023 |
Free cash flow (TTM): | -$150.14M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 72,310,612 as of Feb 21, 2024 |
Index Membership: | S&P 600 Small Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |